Catalyst Pharmaceuticals Inc. (CPRX)
All You Need to Know About Catalyst (CPRX) Rating Upgrade to Strong Buy
Catalyst (CPRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Are Investors Undervaluing Catalyst Pharmaceuticals (CPRX) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Best Value Stocks to Buy for March 4th
CPRX and XP made it to the Zacks Rank #1 (Strong Buy) value stocks list on March 4, 2026.
New Strong Buy Stocks for March 4th
ORN, LRCX, GMED, MYRG and CPRX have been added to the Zacks Rank #1 (Strong Buy) List on March 4, 2026.
Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2025 Earnings Call Transcript
Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2025 Earnings Call Transcript
Catalyst Pharmaceuticals Q4 Earnings Beat, Firdapse Revenues Rise Y/Y
CPRX tops Q4 estimates as Firdapse and Agamree sales jump, lifting 2025 results and driving upbeat 2026 revenue guidance.
Catalyst (CPRX) Reports Q4 Earnings: What Key Metrics Have to Say
The headline numbers for Catalyst (CPRX) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Ahead of Catalyst (CPRX) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Catalyst (CPRX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2025.
Catalyst Pharmaceuticals: Clear Path Forward For Growth In 2 FDA-Approved Drugs
Catalyst Pharmaceuticals management asserts a $1B+ LEMS market opportunity, estimating 3,600–5,400 addressable patients, with growth driven by improved diagnosis and market penetration. Recent presentations highlight 15–20% continuous growth in LEMS, with strategic emphasis on both idiopathic and cancer-associated segments to expand FIRDAPSE's reach. In addition to LEMS, Catalyst controls North American rights to the DMD drug AGAMREE, which is enjoying significant growth.
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Analysts Estimate Catalyst Pharmaceutical (CPRX) to Report a Decline in Earnings: What to Look Out for
Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
